ArticleInternational journal of nanomedicine2026
An AIEgen-Based Carrier Enables Efficient Cytosolic Delivery of Bioactive Proteins.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytosolic protein delivery enables the direct transport of exogenous proteins into the cytoplasm, offering a powerful approach for precise regulation of intracellular activities. This strategy facilitates the investigation of complex physiological processes in cellular and molecular biology and supports the development of protein-based biotechnologies and precision therapeutics, such as targeted protein supplementation for cellular repair or modulation of aberrant cellular functions. However, current delivery methods face some challenges, including cytotoxicity, immune activation, and the difficulty of maintaining protein stability and activity during transport. Methods: Here, we report a novel AIEgen (Aggregation-induced emission luminogen) -based carrier, MTPABP-Guided-Intracellular-Carrier (MAGIC), that achieves high efficiency in delivering native proteins into the cytosol. MAGIC is capable of binding both negatively and positively charged proteins and mediates their intracellular transport via clathrin-mediated uptake with endosomal escape. Results: Notably, the β-Gal and HRP proteins delivered by MAGIC maintain their biological activity after delivery, and the cytotoxicity of MAGIC is approximately 40% lower than that of Lipo8000 and TranEX. MAGIC efficiently delivered trypsin, RNase A, and saporin into the cytosol of mammalian cell lines while preserving their enzymatic or functional activity. Conclusion: This rationally designed AIEgen-based platform provides a versatile and efficient solution for cytosolic protein delivery. The MAGIC delivery system holds significant promise for advancing the study of cellular physiology and enabling precise therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.